In this edition we dare to dream – fever dream, no less – about the future of the NHS. We go beyond the current chaos and ...

ProImmune has announced the launch of its ProVE SL Self-Loading MHC Class I Monomers, a new reagent platform designed to enhance antigen-specific CD8+ T cell detection. The Oxford-based life science ...

Alys Pharmaceuticals has announced the dosing of the first subject in its phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor developed for the treatment of Cold ...

Sonoma Biotherapeutics has announced positive interim results from its ongoing phase 1 Regulate-RA trial evaluating ...

Faster scans and same-day results improve patient experience across community sites United Lincolnshire Teaching Hospitals NHS Trust has upgraded its three Community Diagnostics Centres (CDCs) in ...

Incyte has announced promising new data from its phase 3b TRuE-AD4 trial of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis (AD), revealing significant improvements in clinical ...

Domain Therapeutics has announced the first patients have been dosed in its phase 1/2 DOMISOL clinical trial of DT-7012, a ...

Evotec SE has announced a $25m milestone payment from Bristol Myers Squibb, recognising scientific progress made within their ...

Qureight’s Vascul8 model has been validated in a peer-reviewed study marking a significant advance in the treatment of ...